Companies: 10,795·Total market cap: $144.5T
Gossamer Bio, Inc.

Gossamer Bio, Inc.

GOSSNASDAQHealthcare● Active
$0.17
$-0.01(-5.14%)
Market Cap$38959583
P/E Ratio
52W High$3.87
52W Low$0.163
SEC Filings

Gossamer Bio, Inc. (GOSS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001728117 · GOSS · NASDAQ · as of Jun 8, 2026

Filing snapshot

440
Total Filings
4
Latest Form
2026-06-05
Most Recent
2019
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001728117 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-17
Fiscal Year End
Mar 17, 2026
Accession No.
0001728117-26-000017
Primary Document
goss-20251231.htm
Source: data.sec.gov · CIK 0001728117 · Accession 0001728117-26-000017

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
8-K
2026-06-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-05
View
8-KCurrent Report
8-K
2026-06-05
View
8-KCurrent Report
8-K
2026-06-02
View
PRE 14APRE 14A
PRE 14A
2026-05-18
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-18
View
8-KCurrent Report
8-K
2026-05-18
View
10-QQuarterly Report
10-Q
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-14
View
ARSARS
ARS
2026-04-24
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-24
View
DEF 14AProxy Statement
DEF 14A
2026-04-24
View
8-KCurrent Report
8-K
2026-04-09
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-24
View
EFFECTEFFECT
EFFECT
2026-03-18
View
Showing 1–15 of 246 filingsForm 4 / 144 hidden· 440 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001728117  |  Exchange: NASDAQ · Healthcare

Gossamer Bio, Inc. (NASDAQ: GOSS) has submitted 440 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2019. As a Healthcare sector company with CIK 0001728117, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Gossamer Bio, Inc.'s most comprehensive regulatory disclosure. The most recent Gossamer Bio, Inc. 10-K was filed on 2026-03-17 for fiscal year ending 2026. Historical GOSS 10-K annual reports are available from 2018 through 2026.

Investors researching Gossamer Bio, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

GOSS SEC Filings · 8 questions

Gossamer Bio, Inc. (GOSS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 440 filings and access original documents at no cost. Gossamer Bio, Inc.'s CIK is 0001728117.

GOSS SEC filingsGossamer Bio, Inc. SEC documentsfind GOSS 10-K